"ASF recognizes that rare disease drug development is complicated and challenging. While we await the final decision of the FDA on the use of bardoxolone methyl for Alport syndrome, we want to express our gratitude to the patients for fully enrolling this first clinical study, for participating in the advancement of research for the community of patients and families, and for so openly sharing their insights and experiences at the Advisory Committee meeting. ASF is committed to continued investment in research, to partnering with industry to find better treatments and/or a cure, and improving the lives of people living with Alport syndrome. We are moving forward together with dedication and hope."

-ASF Executive Director Lisa Bonebrake